A carregar...
Therapeutic cancer vaccines and combination immunotherapies involving vaccination
Recent US Food and Drug Administration approvals of Provenge(®) (sipuleucel-T) as the first cell-based cancer therapeutic factor and ipilimumab (Yervoy(®)/anticytotoxic T-lymphocyte antigen-4) as the first “checkpoint blocker” highlight recent advances in cancer immunotherapy. Positive results of th...
Na minha lista:
| Publicado no: | Immunotargets Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918241/ https://ncbi.nlm.nih.gov/pubmed/27471705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S40264 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|